Trial Design Deep Dive: Comparing TROPION-Breast02 and ASCENT-03

The panel turns to the design of two pivotal first-line trials, framing the discussion not as a head-to-head comparison but as a way to inform patient selection in clinic. Panelists walk through where the two studies diverge in ways that matter clinically, including differences in primary versus co-primary endpoints, the presence or absence of a minimum disease-free interval, single-agent versus other control arm choices, and the role of crossover and how it can influence interpretation of survival data. The conversation also touches on regional and population differences across the studies, including representation of PD-L1 status and CNS metastases. The recurring theme is that cross-trial comparisons are inherently limited when designs and populations differ, but those same differences can help clinicians identify which patients may align better with the evidence from one study versus another. Viewers gain a practical framework for reading trial design with treatment selection in mind.